Parkin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Parkin

Property Description
Active ingredient Trihexyphenidyl Hydrochloride
Form Tablet, Oral solution (Elixir)
Pharmacological class Anticholinergic Agent (Antimuscarinic)
Common use Managing symptoms of Parkinsonism and extrapyramidal disorders
Origin Synthetic compound

What Type of Medicine is Parkin (Trihexyphenidyl)?

Parkin is a synthetic, prescription-only medication primarily used to manage certain motor disorders. Its sole active ingredient is Trihexyphenidyl Hydrochloride, also known by its International Nonproprietary Name (INN) Trihexyphenidyl. This active compound is clinically recognized for its specific effects on the central nervous system. The substance is recognized as an essential agent used in Parkinsonism, underscoring its established therapeutic role. It is categorized by health authorities as an Anticholinergic Agent and an Antiparkinson Agent. As a pharmaceutical preparation, Parkin is typically administered via the oral route, with available forms including the tablet and the liquid oral solution (elixir), often used when flexible dosing or ease of swallowing is needed.

How Does Parkin Function to Help Movement Disorders?

Parkin functions as a central anticholinergic that modifies chemical signaling in the central nervous system, helping to re-establish chemical balance in the brain's motor pathways. The drug's mechanism involves acting as an antimuscarinic, specifically blocking the influence of the neurotransmitter acetylcholine on certain receptors. Trihexyphenidyl is commonly used to reduce stiffness and tremors in people with Parkinson's disease. The drug's general therapeutic purpose is to mitigate the excessive nerve impulses that cause abnormal muscle activity. This action supports the overall goal of reducing symptoms such as involuntary tremors, muscle stiffness (rigidity), and poor muscle control in patients diagnosed with Parkinsonism and specific drug-induced extrapyramidal disorders.

Regulatory References

  1. WHO Essential Medicines List
  2. MedlinePlus, NIH

What side effects are possible with Parkin?

Possible Side Effects and Safety Information

The safety profile of Parkin (Trihexyphenidyl Hydrochloride), classified as an Anticholinergic Agent, is based on extensive documentation within official government prescribing labels.


Documented Adverse Reactions

The most frequently reported side effects are categorized as Common, occurring in approximately 30% to 50% of patients according to FDA labeling. These effects are often transient and tend to lessen with continued treatment:

  • Ocular: Blurred vision
  • Gastrointestinal: Dry mouth (xerostomia), mild nausea
  • Nervous System: Dizziness, mild nervousness

Other adverse reactions that affect various organ systems have been documented, including constipation, vomiting, urinary hesitancy, headache, drowsiness, and tachycardia. More complex reactions such as mental confusion, hallucinations, and paranoia have been reported.


Serious Safety Considerations

Regulatory documents highlight rare but clinically critical safety concerns:

  • Neuroleptic Malignant Syndrome (NMS): This potentially fatal syndrome has been reported in association with the abrupt withdrawal or sudden dose reduction of the medication.
  • Glaucoma: The drug may precipitate or worsen narrow-angle glaucoma due to its effect on intraocular pressure.
  • Hyperthermia: Impaired ability to sweat (anhidrosis) poses a risk of heat stroke, particularly during strenuous activity or in hot weather.

Population-Specific Notes

The medicine's effects may require close observation in specific groups. Geriatric patients (over 60) frequently exhibit increased sensitivity to the drug's actions, potentially leading to mental confusion or disturbed behavior more readily. The official label also notes constraints regarding use in patients with Tardive Dyskinesia, as the drug does not alleviate and may aggravate its symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

If you suspect an overdose with Parkin (Trihexyphenidyl), immediate medical attention is required. Contact medical personnel or poison control immediately.

Overdose with this medication may produce symptoms consistent with Central Anticholinergic Syndrome. The official regulatory information documents the following manifestations and required actions:


Documented Overdose Manifestations

System Signs and Symptoms
Central Nervous System Delirium, disorientation, hallucinations, anxiety, agitation, hyperactivity, and potential progression to seizures, stupor, or coma.
Cardiovascular/Respiratory Severe tachycardia, cardiac arrhythmias, and potential for cardiac or respiratory arrest.
Peripheral/Thermoregulation Dry, warm skin, facial flushing, hyperthermia (elevated body temperature), and widely dilated, sluggish pupils (mydriasis).

Required Emergency Actions

Action Regulatory Statement
Immediate Care Immediate medical attention is required if overdose is suspected. Call emergency services if the individual has collapsed, is having a seizure, has trouble breathing, or cannot be awakened.
Management Supportive and symptomatic therapy is required. Gastric lavage may be indicated. The regulatory profile notes that Physostigmine may be used to reverse central and peripheral effects.
Population Note Untreated overdose may be fatal, especially in children.

Close monitoring of cardiac and respiratory function, along with observation of vital signs, is necessary during management.

Therapeutic Uses of Parkin

What Parkin Treats: Main Uses and Benefits

Parkin (Trihexyphenidyl) is commonly used across conditions characterized by periods of heightened symptoms of movement disorders. The medication is relevant for easing symptoms related to increased neurological or muscular activity in various clinical settings.


Managing Primary Parkinsonism Symptoms

Parkin is applied in addressing the core motor symptoms of Parkinsonism, including idiopathic, postencephalitic, and arteriosclerotic types. It is commonly used to help with reducing involuntary tremors and persistent muscle rigidity (stiffness), which are symptoms that interfere with daily functioning. This contributes to easing the overall symptom load and assists with supporting functional stability, particularly during symptomatic periods.


Treating Medication-Induced Movement Side Effects

The drug is also used for managing Extrapyramidal Disorders (EPS), which are specific symptom clusters that may become intense or disruptive after treatment with certain central nervous system medications. This includes supporting the stabilization of acute manifestations, such as sudden muscle spasms or dystonia. The medication is relevant for managing both primary Parkinson's symptoms and medication-induced side effects.

“This medication provides support that helps ease the overall symptom burden in situations where short-term symptomatic assistance is needed.”

Quick Fact: Relief for Motor Symptoms

Parkin is commonly used to provide supportive relief for symptoms related to tremor, muscle rigidity, and involuntary spasms across various parkinsonian and drug-induced movement disorders.

Regulatory References

  1. NIH DailyMed official drug information

Eligibility and Restrictions for Use

Contraindications (Must Not Use)

Parkin (Trihexyphenidyl) is strictly contraindicated in specific patient groups according to regulatory guidelines. The medicine must not be used by individuals with a documented Hypersensitivity to the drug or by patients diagnosed with Narrow Angle Glaucoma. Certain regulatory documents also list Ileus as an absolute exclusion.

Conditional Use and Restrictions

Use is permitted under caution for several populations. Close monitoring is required for patients with cardiac, liver, or kidney disorders, as well as those with hypertension. Caution is mandatory for individuals with obstructive diseases of the gastrointestinal or genitourinary tract (e.g., prostatic hypertrophy) and for those with Arteriosclerosis.

Age and Status Limitations

Safety and efficacy are not established in the pediatric population, resulting in use being generally not recommended. Older adults (over 60) are eligible but are noted to have increased sensitivity and require close oversight. Use during pregnancy and lactation is generally not recommended by regulatory bodies due to unknown risks and potential effects on the infant or on lactation.

What should I know about interactions with other medicines?

Parkin (Trihexyphenidyl) interactions are primarily defined by pharmacodynamic augmentation and specific pharmacokinetic interference, as documented in regulatory sources.

Co-administration with other Anticholinergic Agents, including tricyclic antidepressants or MAOIs, is noted to result in the intensification of anticholinergic effects. The official prescribing information advises that combining Parkin with substances that act as Central Nervous System (CNS) Depressants, such as alcohol, opiates, or barbiturates, can lead to additive sedative effects; the use of alcohol is advised to be avoided.

A key pharmacokinetic interaction is documented with Levodopa, where co-administration reduces the absorption and peak plasma concentration (Cmax) of Levodopa due to delayed gastric emptying. Regulatory constraints specify that if these two medicines are used together, the usual dosage of each may require reduction. Furthermore, combination with certain Neuroleptics is noted to increase the risk for the development of Tardive Dyskinesia. Parkin may also exhibit an antagonistic effect on gastrointestinal function when used with Prokinetic Agents like metoclopramide. Population-specific cautions exist, indicating that the elderly and chronically ill are more susceptible to severe anticholinergic effects when combining atropine-like drugs, particularly in hot environmental conditions. The official documents classify interactions as requiring adjustment or caution, with no drug-drug combinations formally listed as contraindicated.

Mechanism of Action

Modulating the Central Cholinergic System in Motor Pathways

This section covers the drug's primary action as an antagonist at central muscarinic acetylcholine receptors ( M1) located in the basal ganglia. By blocking the excitatory effect of acetylcholine, the drug directly influences the dopamine-acetylcholine balance , leading to the physiological modulation of excessive nerve impulses that pass through motor circuits.


Antagonizing Peripheral Parasympathetic Impulses

The mechanism extends peripherally by blocking muscarinic receptors on glands and smooth muscle tissues throughout the body. This antimuscarinic action inhibits the transmission of efferent parasympathetic nerve signals, which is associated with a diminution of involuntary smooth muscle contraction (spasmolytic activity) and modifies the secretion of fluids from affected glands.

Dosage and Administration Information

How to Use Parkin (Trihexyphenidyl): Official Administration Guidelines

Parkin (Trihexyphenidyl) is administered solely via the oral route using the approved tablet or oral solution (elixir) forms. Standard clinical protocols establish a method for initiating and maintaining the required daily intake, emphasizing an individualized approach.


Standard Dosing and Schedule

The typical process involves starting with a low dose and gradually increasing the amount over several days. The initial dose for primary Parkinsonism is 1 mg on the first day, with subsequent increments of 2 mg added every 3 to 5 days until the effective level is found. Most patients achieve maintenance on a total daily dose between 6 mg and 10 mg, although up to 15 mg may be necessary for some conditions. For managing drug-induced extrapyramidal symptoms, the total daily amount typically ranges from 5 mg to 15 mg.

The total daily dose must be divided into multiple parts—usually three doses taken at mealtimes—to maintain a consistent effect. Higher daily doses may require division into four parts, with the final dose administered at bedtime.


Contextual and Population-Specific Use

Administration timing relative to food is determined by the patient’s experience: taking the medicine before meals may help if dry mouth is prominent, while taking it after meals may be preferred if nausea occurs. When used alongside Levodopa, the dose of Trihexyphenidyl is generally reduced to 3 mg to 6 mg daily in divided doses.

For older adults (over 60 years), it is generally advised to start with a lower dose and increase it gradually. Treatment is often a long-term plan, and abrupt discontinuation is prohibited; the dose must be reduced gradually over several days to avoid an acute return of symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section describes the main research that has examined the drug. The information below is purely descriptive and does not constitute medical advice or a recommendation for use.


Acute Gout Flare Studies (Monotherapy)

Studies have been conducted to measure changes in pain scores in participants with acute gout flare.

Key Findings on Pain and Swelling

  • Pain Score Measurement: Research has explored the primary endpoint of change in pain score for patients with acute gout flare. One key study reported findings at the 3-hour time point detailing the mean change in pain score. Another trial explored the mean difference in pain scores at 24 and 48 hours post-dose compared to an inert placebo.
  • Joint Swelling: Research examined the mean difference in joint swelling scores between participants receiving the drug and those receiving placebo. A difference in the mean duration of symptoms was included as a secondary finding in the studies.
  • Study Doses: The trials primarily focused on one specific dosage level, although multiple levels were evaluated for comparison during the study design.

Combination and Off-Label Use Research

While the drug is primarily studied as a monotherapy for acute gout, limited research has examined its use in other settings.

Combination Therapy

Combination therapy with Drug Y was evaluated in one study, examining its use in participants with severe pain. The study compared outcomes of participants receiving the combination versus those receiving the drug alone. The findings did not show a clear difference for any significant difference in primary outcomes.

Safety Profile in Specific Populations

The latest research examined the safety profile of the treatment in elderly patients. The findings included data on the adverse event rate in participants aged 65 and older, which was observed to be similar to the rate reported for the general study population.

Frequently Asked Questions (FAQ)

Common questions about Parkin (FAQ)


Q: What happens if I accidentally miss a dose of Parkin?

Official information generally outlines that a missed dose may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the regulatory guidance indicates that the missed dose is typically skipped, and the regular schedule is followed. It is stated that double or extra doses should not be taken to compensate for a missed dose.


Q: Can I drink coffee or tea while I'm taking Parkin?

Core regulatory documents do not list a specific contraindication for consuming caffeine in coffee or tea while taking Parkin. Caution is generally advised with other substances that may cause similar central nervous system (CNS) stimulation. Any concerns, such as increased jitteriness or anxiety, should be discussed with a healthcare professional.


Q: How long does the effect of one dose of Parkin usually last?

The total daily dose is typically divided and taken in three to four parts to maintain a consistent effect throughout the day. This schedule is necessary because the drug's elimination half-life, the time it takes for the concentration to reduce by half in the body, is relatively short. Therefore, taking the medicine consistently is indicated to maintain a therapeutic level.


Q: Can Parkin be used for conditions other than Parkinson's disease?

Yes, Parkin (trihexyphenidyl) is indicated for use beyond primary Parkinsonism (such as idiopathic and arteriosclerotic types). It is also officially prescribed as an adjunct treatment for postencephalitic parkinsonism and to help control extrapyramidal reactions (unwanted movements) caused by certain other medications.


Q: Do you have to stop taking Parkin suddenly or taper off?

Regulatory warnings state that stopping Parkin abruptly is strictly prohibited. This is due to the risk of a severe worsening of parkinsonian symptoms or a potentially fatal condition called Neuroleptic Malignant Syndrome (NMS). Official guidance requires that any discontinuation or reduction of the dose be performed gradually and under the supervision of a healthcare professional.


Q: Does Parkin affect vision or eyesight?

The official label lists blurred vision as a common side effect of Parkin. More seriously, the drug's action may precipitate or worsen narrow-angle glaucoma due to its effect on the pressure within the eye. Any sudden changes in vision or eye pain are noted as symptoms that warrant seeking professional medical evaluation.


Q: Can Parkin be crushed or split if a patient has trouble swallowing?

Parkin is available as an oral solution (elixir) in addition to the tablet form, which is often used for patients who have trouble swallowing. While standard tablets may sometimes be manipulated, official guidance warns against crushing sustained-release products. It is necessary to confirm the appropriate method of administration with a healthcare professional, particularly when a patient has difficulty swallowing the tablet form.


Q: Is Parkin used for the early stages of Parkinson's?

Official regulatory information describes a gradual titration schedule for initiating treatment for idiopathic parkinsonism, starting at a low dose. This suggests that the medicine is considered appropriate for use in initial or early treatment plans for managing symptoms.


Q: Are there specific foods I should avoid when taking Parkin?

There are no specific foods that official documents advise against avoiding when taking Parkin. The only guidance regarding meals is to adjust the timing of the dose—either before or after eating—based on whether an individual experiences dry mouth or nausea, respectively.


Q: Does Parkin cause any digestive problems like nausea?

Yes, common adverse reactions listed in the official safety profile include digestive issues. These frequently reported side effects include dry mouth (xerostomia), mild nausea, constipation, and vomiting.


Q: What's the mechanism that causes some of the common side effects of Parkin?

Parkin acts as an anticholinergic agent, which means it inhibits the parasympathetic nervous system throughout the body. This inhibitory effect is responsible for many of the common side effects, such as dry mouth (by decreasing salivation), blurred vision (by affecting the eye muscles), and constipation (by slowing digestive motility).


Q: Is Parkin the same as other Parkinson's medicines like levodopa?

No, Parkin (trihexyphenidyl) is classified as an anticholinergic agent, which works by affecting chemical signaling balance in the central nervous system. Levodopa, conversely, is a medicine that is converted into dopamine. These are different classes of drugs, although they are frequently used together for the comprehensive management of Parkinsonism.


Q: Is there a generic version of Parkin available?

Yes, Parkin is a brand name, and the active ingredient, trihexyphenidyl hydrochloride, is widely available as a generic drug, which is listed in official government drug approval records.


Q: What kind of studies support the use of Parkin for movement symptoms?

The FDA label supports the use of Parkin based on clinical data demonstrating its therapeutic effect as a central anticholinergic. It is shown to reduce stiffness and tremors by relaxing smooth musculature and balancing chemical signaling in the brain's motor pathways.


Q: Is it possible to become dependent on Parkin?

While regulatory documents do not use the specific term 'dependence,' they issue a strong warning against the abrupt discontinuation of the medicine. This is because sudden cessation can lead to a severe worsening of symptoms or Neuroleptic Malignant Syndrome, indicating that the body relies on the ongoing presence of the drug to maintain symptom control.


Q: Are there any known interactions between Parkin and alcohol?

Yes, the use of alcohol is advised to be avoided while taking Parkin. This is because both substances are considered Central Nervous System (CNS) depressants, and using them together can lead to increased effects such as drowsiness, sedation, and dizziness.


Q: Does Parkin help with the tremor or mainly with stiffness?

Parkin is used to reduce both tremor and rigidity (stiffness) associated with Parkinson's disease. Clinical data has noted it may be particularly effective for managing the involuntary tremor symptoms.


Q: Is it safe to drive while taking Parkin?

Official warnings state that Parkin can cause side effects such as drowsiness, dizziness, and blurred vision, which may impair judgment and motor skills. Caution is advised when operating machinery or driving until the individual knows how the medicine affects their alertness and vision.


Q: Why is Parkin sometimes given with another drug?

Parkin is frequently given as an adjuvant therapy, meaning it is used alongside another main treatment, such as levodopa, to manage Parkinsonism. It is also combined with tranquilizers to effectively manage drug-induced extrapyramidal movement symptoms.


Q: Is the research on Parkin recent or has it been around for a while?

Parkin (trihexyphenidyl) is an established medicine that has been around for a while. The drug was first granted approval by the U.S. Food and Drug Administration (FDA) in 1949.


Q: What if I experience unusual dreams or vivid thoughts while on Parkin?

Official adverse reaction reports include mental confusion, agitated behavior, and hallucinations as possible side effects. Official documentation notes that symptoms like unusual dreams, vivid thoughts, or other changes in mental state are conditions for which professional medical guidance is necessary.


Q: Is it better to take Parkin in the morning or evening?

The total daily dose is typically divided and taken at mealtimes, though higher doses may include a fourth dose at bedtime. The specific timing of when to take the divided doses (morning, noon, evening) is determined individually based on the patient's reaction to potential side effects like dry mouth or nausea.


Q: Is Parkin approved in other countries besides the U.S.?

Yes, the drug with the active ingredient trihexyphenidyl is authorized and listed in the national medicine registers of multiple countries outside of the United States, including nations within the European Union.


Q: Will Parkin cure Parkinson's disease?

No. Official patient information from government sources clearly states that Parkin (trihexyphenidyl) is used only to manage and mitigate symptoms like stiffness and tremors associated with parkinsonism. It does not cure the underlying condition.


Q: Can Parkin interact with natural supplements like St. John's Wort?

While St. John's Wort is not explicitly listed on the official Parkin label, caution should be exercised. This supplement can potentially interact with many drugs that affect the central nervous system (CNS), leading to additive effects such as increased sedation or drowsiness.

How should Parkin be stored and disposed of?

Storage and Disposal Requirements for Parkin (Trihexyphenidyl)

Parkin must be stored according to official regulatory requirements to maintain its stability and effectiveness.

Storage Conditions

Detail Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep protected from light, moisture, and excessive heat; do not freeze the oral solution.
Safety Keep out of the sight and reach of children and store in a tight, light-resistant container with a child-resistant closure.

Disposal Instructions

Unused or expired Parkin must be disposed of properly. Do not throw the medication away via wastewater or household waste. The product should be disposed of in accordance with local requirements, often by utilizing an approved drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Parkin found in:

A-Z Index: